The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Remaining unmet needs in mesothelioma
Peter Szlosarek, MD, PhD, Barts Cancer Institute, London, UK, describes unresolved issues regarding the management of mesothelioma, which currently has limited treatment options and low five year survival rates. Chemoimmunotherapy involving durvalumab or pembrolizumab with pemetrexed and platinum have shown encouraging signals. Prof. Szlosarek additionally highlights targeting tumor suppressors. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
